{
    "nct_id": "NCT05998135",
    "official_title": "Phase II Clinical Trial Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer",
    "inclusion_criteria": "* Patients with platinum-resistant, high-grade serous ovarian cancer, defined as disease progression within six months of completion of their last platinum-based chemotherapy\n* Patients must maintain Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* There will be no limitations on number of prior lines of therapy\n* Trial is open to non-English speaking patients\n* Trial is open to patients referred from community practice\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Patients who are < 18 years old\n* Patients who are pregnant or breastfeeding (due to cancer of their reproductive organs, patients enrolled in the trial are unable to conceive)\n* Patients who are incarcerated\n* Patients who are unable to provide consent / lack decision-making capacity",
    "miscellaneous_criteria": ""
}